In the spotlight Ramatu - US Jan 31, 2026
He mentioned, "There hasn't been a notable opposition from our members in challenging these items, possibly because they don't meet the criteria under 503A." According to Section 503A of the Food, Drug & Cosmetic Act, an eligible bulk drug substance for compounding must be a component of an FDA-approved drug, must have a USP or NF monograph, or must appear on the FDAs 503A Bulks List or Interim Bulks List Category 1
"People do sometimes think, 'What is this man doing?'" But Marvin's confident it's helping him achieve the appearance he desires - a hollow-cheeked, chiselled profile with sharp, pointed eyes and strong jawline
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a Phase 2 trial
If you havent explored mobility aids for senior dogs, those small environmental changes can also reduce daily strain on damaged joints